A new 4,5-diaryl-lH-imidazole was synthesized and characterized by 1H NMR, ESI-MS, elemental analysis and FT-IR. The crystal structure of the title compound （C19H16C12N202, Mr = 375.24） has been determined by single...A new 4,5-diaryl-lH-imidazole was synthesized and characterized by 1H NMR, ESI-MS, elemental analysis and FT-IR. The crystal structure of the title compound （C19H16C12N202, Mr = 375.24） has been determined by single-crystal X-ray diffraction. Crystal parameters： mono- clinic system, space group P2/n, a = 14.349（3）, b = 8.7918（18）, c = 15.352（3） A, β = 108.56（3）°, V = 1836.1（6） A3, Z = 4, F（000） = 776, Dc = 1.357 g/cm3, p = 0.368 mm-1, the final R = 0.0502 and wR = 0.1066 for 2324 observed reflections with 1 〉 2 σ（/）. A total of 16117 reflections were collected, of which 3615 were independent （Rint = 0.0595）. The preliminary bioassay suggested that the title compound exhibits distinct effective inhibition on the proliferation of cancer cell lines.展开更多
基金Supported by the National Undergraduate Training Programs for Innovation and Entrepreneurship(No.101422013067)
文摘A new 4,5-diaryl-lH-imidazole was synthesized and characterized by 1H NMR, ESI-MS, elemental analysis and FT-IR. The crystal structure of the title compound （C19H16C12N202, Mr = 375.24） has been determined by single-crystal X-ray diffraction. Crystal parameters： mono- clinic system, space group P2/n, a = 14.349（3）, b = 8.7918（18）, c = 15.352（3） A, β = 108.56（3）°, V = 1836.1（6） A3, Z = 4, F（000） = 776, Dc = 1.357 g/cm3, p = 0.368 mm-1, the final R = 0.0502 and wR = 0.1066 for 2324 observed reflections with 1 〉 2 σ（/）. A total of 16117 reflections were collected, of which 3615 were independent （Rint = 0.0595）. The preliminary bioassay suggested that the title compound exhibits distinct effective inhibition on the proliferation of cancer cell lines.
